Spruce Biosciences (SPRB) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tonix Pharmaceuticals (TNXP) has outperformed Spruce Biosciences (SPRB) over the past year, losing 67.2% versus a loss of 75.7%. Over five years, SPRB leads with a -99.8% price change compared with -100.0% for TNXP. Tonix Pharmaceuticals is the larger company by market cap ($129.5 million vs $127.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SPRB | TNXP |
|---|---|---|
| Share price | $44.40 | $7.55 |
| Market cap | $127.61M | $129.49M |
| 1-day change | +3.77% | -1.88% |
| YTD return | -49.03% | -51.66% |
| 1-year return | -75.68% | -67.17% |
| 5-year return | -99.82% | -100.00% |
| Forward P/E | 8.92 | — |
| EPS (TTM) | $-39.12 | $-13.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $199.20 | $23.25 |
| 52-week low | $40.33 | $7.42 |
| Distance from 52-week high | -77.71% | -67.53% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +233.33% | +489.40% |
| Average volume | 77.72K | 537.24K |
| Shares outstanding | 2.87M | 17.15M |
| Employees | 22 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Spruce Biosciences
SPRB stock →Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
SPRB vs TNXP FAQ
Which is bigger, Spruce Biosciences or Tonix Pharmaceuticals?
Tonix Pharmaceuticals (TNXP) is larger, with a market capitalization of $129.49M compared with $127.61M for Spruce Biosciences (SPRB).
Which stock has performed better over the past year, SPRB or TNXP?
TNXP returned -67.17% over the past 12 months, compared with -75.68% for SPRB (price return, excluding dividends). Past performance does not predict future results.
Are Spruce Biosciences and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.